6,465 Shares in Mirum Pharmaceuticals, Inc. $MIRM Acquired by Great Lakes Advisors LLC

Great Lakes Advisors LLC acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,465 shares of the company’s stock, valued at approximately $757,000.

A number of other institutional investors have also recently added to or reduced their stakes in MIRM. Nan Fung Trinity HK Ltd. boosted its holdings in Mirum Pharmaceuticals by 45.6% in the fourth quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock worth $17,969,000 after purchasing an additional 71,214 shares in the last quarter. Emerald Advisers LLC increased its position in Mirum Pharmaceuticals by 8.2% during the first quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock worth $36,699,000 after buying an additional 30,129 shares during the last quarter. SBI Okasan Asset Management Co.Ltd. bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at about $1,283,000. Hillsdale Investment Management Inc. bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at about $3,762,000. Finally, Rice Hall James & Associates LLC bought a new position in Mirum Pharmaceuticals during the second quarter valued at about $12,956,000.

Insider Activity at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 6,001 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the transaction, the chief financial officer owned 36,355 shares in the company, valued at approximately $3,631,864.50. The trade was a 14.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the transaction, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. The trade was a 96.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 133,156 shares of company stock worth $13,763,562 in the last ninety days. 8.32% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $96.31 on Friday. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The stock’s 50 day moving average price is $111.20 and its two-hundred day moving average price is $101.94. The firm has a market capitalization of $6.25 billion, a P/E ratio of -6.62 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 12-month low of $63.23 and a 12-month high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm’s revenue was up 37.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.12) earnings per share. On average, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.

Wall Street Analyst Weigh In

MIRM has been the subject of several recent analyst reports. HC Wainwright decreased their price target on Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Morgan Stanley set a $137.00 price objective on Mirum Pharmaceuticals in a research note on Thursday, August 6th. Wolfe Research began coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 target price for the company. Citizens Jmp reduced their target price on Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their target price on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.33.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.